On 6 June 2023, Sareum announced the successful dosing of the first subjects in a Phase 1a (single ascending dose) clinical trial for its lead programme SDC-1801. The dosing has started at a specialist clinical unit in Melbourne, Australia. The Phase 1a trial is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral formulation of SDC-1801 in healthy subjects. This will be a randomised, placebo-controlled trial with single and multiple ascending oral d ....
